Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®

PHILADELPHIA, Sept. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Trademark Office for its SYMPHONY and PRELUDE trademarks, as used with Echo's tCGM system and mechanical skin ablator, respectively.  The Certificate of Registration for the SYMPHONY trademark was issued on August 2, 2011, and for the PRELUDE trademark on July 26, 2011.

The registration gives Echo exclusive nationwide rights to use the SYMPHONY and PRELUDE trademarks on or in connection with the associated products, potentially in perpetuity.

"We are pleased to receive these registered trademarks in connection with our Symphony tCGM System and Prelude SkinPrep System.  They are valuable pieces of intellectual property for Echo as we continue to grow and protect our brands," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "This achievement marks another important step in the commercialization of Symphony and Prelude."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine Olimpio
Director, Corporate Communications
(215)717-4104

Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.